Of the 2674 NSCLC patients enrolled, 1322 (49.5%) were positive for PD-L1 expression (TPS ≥ 1%), with 467 (17.5%) showing strong positive (TPS ≥ 50%) (Table 1). The gene discussed is CD274; the disease is non-small cell lung carcinoma.